Windtree Therapeutics Inc
NASDAQCM:WINT
United States / Healthcare / Biotechnology
Exchange Data
Hide this widget
Price
1.56 USD
Day change
-0.08 (-4.88%)
52-week range
1.45 - 737.43
19:59 - Closed
Pre Market1.69 +0.05 (+3.05%)
Summary of Windtree Therapeutics Inc
Hide this widget
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. T...
Price History
Chart Gallery
Hide this widget
1 Week
1 Month
3 Months
1 Year
5 Year
10 Years
- (-)
Data Explorer
Hide this widget
Data could not be retrieved
Peer Benchmarks
Hide this widget
Quote
Value
Size
Growth
Profit
| WINT | Peers | Sector | |
|---|---|---|---|
Market Cap | 1.169 M | 280.8 M | 64.213 M |
Price % of 52 Week High | Premium | 33.7% | 62.0% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | Premium | -41.2% | -0.7% |
1 Year Price Total Return | -99.5% | -40.4% | -12.0% |
Beta (5 Year) | 0.68 | 1.48 | 0.64 |
In the News
Hide this widget
Fair Value
Hide this widget
Average
–
Upside
–
Uncertainty
–
Spread
–
Financial Health
Health Details
Hide this widget
Financial Health for Windtree Therapeutics is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.
12345
Financial Models for Windtree Therapeutics Inc
Model Gallery
Hide this widget
| DuPont ROE AnalysisView Updated 5 days ago |
| 10Y Historical FinancialsView Updated 5 days ago |
| 5Y Historical FinancialsView Updated 5 days ago |
| CAPM WACC ModelView Updated 14 hours ago |
| 10Y DCF EBITDA ExitView Updated 20 hours ago |
| 10Y DCF Revenue ExitView Updated 20 hours ago |
| 10Y DCF Growth ExitView Updated 20 hours ago |
| 5Y DCF EBITDA ExitView Updated 20 hours ago |
| 5Y DCF Revenue ExitView Updated 20 hours ago |
| 5Y DCF Growth ExitView Updated 20 hours ago |
| Earnings Power ValueView Updated 20 hours ago |
Historical Financials
Full Financials
Hide this widget
| (USD in thousands) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Sept-24 | Sept-23 | Sept-24 |
| Income Statement | |||||
| Revenue | |||||
| Operating Income | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Net Profit | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Diluted EPS | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| EBITDA | |||||
| Balance Sheet | |||||
| Cash & ST Invest. | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Equity | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Debt | 0.02 | 0.02 | 0.00 | 0.02 | 0.00 |
| Cash Flow Statement | |||||
| Cash Flow Operations | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Investing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Financing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Free Cash Flow | (0.02) | (0.01) | (0.02) | 0.00 | (0.01) |
Analyst Notes
March 29, 2025
Hide this widget